2025-10-30 10:20Financial Performance - The company's operating revenue for the third quarter was RMB 316,386,318.62, a decrease of 34.87% compared to the same period last year[4] - The total profit for the quarter was RMB 19,505,811.07, reflecting a significant decline of 81.85% year-over-year[4] - The net profit attributable to shareholders was RMB 19,773,668.63, down 80.11% from the previous year[4] - The net profit after deducting non-recurring gains and losses was RMB 5,992,555.81, a decrease of 92.94% year-over-year[4] - Basic earnings per share for the quarter was RMB 0.03, down 76.92% compared to the same period last year[5] - Total operating revenue for the first three quarters of 2025 was CNY 984,961,529.76, a decrease of 26.3% compared to CNY 1,335,156,050.40 in the same period of 2024[20] - Operating profit for the first three quarters of 2025 was CNY 99,452,028.34, compared to a loss of CNY 69,661,013.72 in the same period of 2024[21] - Net profit for the first three quarters of 2025 reached CNY 80,706,047.32, a significant recovery from a net loss of CNY 74,244,009.94 in 2024[21] - The total revenue from the beginning of the year to the reporting period decreased by 26.23% due to market competition[10] - Total profit for the reporting period dropped by 81.85%, primarily due to compressed profit margins on sales orders[10] Cash Flow and Assets - The cash flow generated from operating activities for the year-to-date was RMB 266,391,149.32, an increase of 38.51%[4] - The total assets at the end of the quarter were RMB 9,533,382,709.22, an increase of 1.46% from the end of the previous year[5] - Current assets totaled CNY 5,313,064,269.17 as of September 30, 2025, compared to CNY 5,031,197,927.38 at the end of 2024, marking a growth of 5.6%[19] - Non-current assets decreased to CNY 4,220,318,440.05 from CNY 4,364,954,683.07, indicating a decline of 3.3%[19] - The company's cash and cash equivalents were CNY 902,060,508.84 as of September 30, 2025, down from CNY 965,203,128.59 at the end of 2024[18] - The company reported a net cash flow from operating activities of CNY 266,391,149.32, an increase from CNY 192,325,709.34 in the previous period, reflecting a growth of approximately 38.5%[25] Shareholder Information - The equity attributable to shareholders was RMB 8,120,652,590.12, reflecting a slight increase of 0.52% from the previous year-end[5] - The number of ordinary shareholders at the end of the reporting period was 96,458[12] - Basic and diluted earnings per share were both CNY 0.11, a turnaround from a loss of CNY -0.09 per share in the prior period[22] Business Operations - The laboratory services business contributed a net profit of RMB -156,891,000, a decline of 9101.32% year-over-year[6] - The fair value changes of biological assets contributed a net profit of RMB 140,167,300 for the year-to-date[6] - Revenue for the reporting period decreased by 34.87% due to a decline in sales order prices influenced by market competition[10] - Net profit attributable to shareholders decreased by 80.11%, impacted by reduced profit contributions from laboratory services[10] Comprehensive Income - The total comprehensive income attributable to the parent company was CNY 74,225,847.58, a significant recovery from a loss of CNY -75,166,260.86 in the previous period[22] - The company reported other comprehensive income attributable to the parent company of CNY -6,480,220.42, worsening from CNY -4,859,185.75 in the previous period[22]